Acelyrin, Tang Capital and Poison Pill
Acelyrin Adopts Poison Pill as Tang Capital Partners Builds Stake
The late-stage biopharma said the plan will issue one right for each share of common stock as of the close of business on March 24. The rights will initially trade with its common stock, and will become exercisable only if any person acquires 10% or more of Acelyrin's outstanding common stock.
Pliant follows in the footsteps of Acelyrin, which also enacted a stockholder rights program on Thursday to protect ...
Acelyrin has declined a surprise offer from Concentra Biosciences, and is instead p | Acelyrin consulted with independent ...
Alumis Inc.'s twice-a-day oral drug totally cleared the skin of telltale red, itchy patches in nearly 39% of 80 ...
Concentra Biosciences offers $3/share + CVR for Acelyrin, outperforming Alumis' bid. Read why I rate SLRN stock a Sell at ...
The Rights Plan is effective immediately and will expire on March 12, 2026. ACELYRIN stockholders do not need to take any further action at this time.
Mechelen, Belgium; February 17, 2025, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification and 13D filing from Tang Capital.
LOS ANGELES - Acelyrin Inc. (NASDAQ: SLRN), a biopharmaceutical company specializing in immunology treatments, has implemented a stockholder rights plan following Tang Capital Partners ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback